^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CGX1321

    i
    Company:
    Curegenix
    Drug class:
    Wnt signalling pathway inhibitor, PORCN inhibitor
    Related drugs:
    Apply
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946)
    Phase 1b
    Curegenix Inc.
    Recruiting
    Last update posted :
    01/26/2022
    Initiation :
    02/01/2016
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321